Kiapour AM, Cao J, Young M, Capellini TD. The role of Gdf5 regulatory regions in development of hip morphology. PLoS One. 2018;13(11):e0202785. doi:10.1371/journal.pone.0202785
Shoop WL, Xiong Y, Wiltsie J, et al. Anthrax lethal factor inhibition. Proc Natl Acad Sci U S A. 2005;102(22):7958-63. doi:10.1073/pnas.0502159102
Sundberg TB, Choi HG, Song JH, et al. Small-molecule screening identifies inhibition of salt-inducible kinases as a therapeutic strategy to enhance immunoregulatory functions of dendritic cells. Proc Natl Acad Sci U S A. 2014;111(34):12468-73. doi:10.1073/pnas.1412308111
Giera S, Deng Y, Luo R, et al. The adhesion G protein-coupled receptor GPR56 is a cell-autonomous regulator of oligodendrocyte development. Nat Commun. 2015;6:6121. doi:10.1038/ncomms7121
Geller LT, Barzily-Rokni M, Danino T, et al. Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine. Science. 2017;357(6356):1156-1160. doi:10.1126/science.aah5043
Tripp CS, Cuff C, Campbell AL, et al. RPC4046, A Novel Anti-interleukin-13 Antibody, Blocks IL-13 Binding to IL-13 α1 and α2 Receptors: A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation First-in-Human Study. Adv Ther. 2017;34(6):1364-1381. doi:10.1007/s12325-017-0525-8
Shaw SY, Westly EC, Pittet MJ, Subramanian A, Schreiber SL, Weissleder R. Perturbational profiling of nanomaterial biologic activity. Proc Natl Acad Sci U S A. 2008;105(21):7387-92. doi:10.1073/pnas.0802878105
Martins MM, Zhou AY, Corella A, et al. Linking tumor mutations to drug responses via a quantitative chemical-genetic interaction map. Cancer Discov. 2015;5(2):154-67. doi:10.1158/2159-8290.CD-14-0552
Shaw SY, Tran K, Castoreno AB, et al. Selective modulation of autophagy, innate immunity, and adaptive immunity by small molecules. ACS Chem Biol. 2013;8(12):2724-33. doi:10.1021/cb400352d
Gallenne T, Ross KN, Visser NL, et al. Systematic functional perturbations uncover a prognostic genetic network driving human breast cancer. Oncotarget. 2017;8(13):20572-20587. doi:10.18632/oncotarget.16244